News United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
536.12 ^USD	+0.62%		+12.12%	+10.03%

03-12	Sleep Number Corporation Appoints Kelly F. Baker as Principal Accounting Officer, Effective March 11, 2026	CI
03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI

All News

03-12	Sleep Number Corporation Appoints Kelly F. Baker as Principal Accounting Officer, Effective March 11, 2026	CI
03-11	United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine	BU
03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI
03-09	BETA Technologies Participates In FAA?s eVTOL Integration Pilot Program Across 10 States	CI
03-09	United Therapeutics Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 01:00 PM
03-09	United Therapeutics Corporation authorizes a Buyback Plan.	CI
03-09	United Therapeutics Corporation announces an Equity Buyback for $2,000 million worth of its shares.	CI
03-09	United Therapeutics unveils $2 bln buyback plan, launches $1.5 bln accelerated repurchase	RE
03-09	United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program	BU
03-05	United Therapeutics Insider Sold Shares Worth $4,744,467, According to a Recent SEC Filing	MT
03-05	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says	MT
03-05	UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating	MT
03-03	United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference	BU
03-02	United Therapeutics Corporation - Special Call
03-02	United Therapeutics Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM
03-02	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy	CI
03-02	United Therapeutics Corporation announces ralinepag achieved 55% reduction in risk of clinical worsening in pivotal pulmonary arterial hypertension study, delivering exceptional, highly statistically significant efficacy	RE
03-02	United Therapeutics Says Ralinepag Cut Risk of Clinical Worsening by 55% in Phase 3 Study	MT
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
03-02	United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study	RE
03-02	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy	BU
02-26	United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says	MT
02-26	Oppenheimer Adjusts United Therapeutics Price Target to $600 From $575, Maintains Outperform Rating	MT
02-26	RBC Raises Price Target on United Therapeutics to $643 From $587, Keeps Outperform Rating	MT
02-25	United Therapeutics Corporation, Q4 2025 Earnings Call, Feb 25, 2026